Dr. Stevens is a business development professional that has successfully worked with several different companies.  As Vice President of Business Development for Granlen, a chemistry-based contract research organization (based in Zhengzou, China), he assisted in building a very sustainable and growing business overseas.  Most recently, he has been working with a group of independent business professionals to improve the profitability of several different organizations.  Prior to engaging in business development, Dr. Stevens spent several years working with Exelixis where he was instrumental in leading two major projects to partnership and clinical trials.  In total, the mineralocorticoid antagonist (MR) program provided Exelixis with over $70 million in guaranteed near-term payments, over $1 billion in potential development and commercialization milestones, and substantial royalties.  The liver X receptor program was partnered with Bristol-Myers Squibb for up-front payments of $17.5 million and research and development funding of about $10 million per year over an initial two-year period.  Exelixis was also entitled to $140 million in development and regulatory milestone payments per product for up to two products as well as downstream royalties.

Dr. Stevens received a B.Sc. from Virginia Commonwealth University, a M.A. from Lehigh University in Physical Organic Chemistry, and a Ph.D. in Bioorganic Chemistry from the University of Virginia.  He was a NIH psychoneuroimmunology postdoctoral trainee with the Minneapolis Medical Research Foundation at the University of Minnesota where he discovered the most potent non-peptide antagonist of the kappa-opioid receptor.